Fortrea Holdings Inc. (FTRE)

In the past six months, Fortrea Holdings, Inc. stock has experienced notable gains, with returns of 48.1% over the last 7 days, 73.6% over the last 30 days, and 177.8% over the last year, although it had a 7.0% decline year-to-date as of early May 2026. Key events include reporting first-quarter 2026 results with adjusted EPS of $0.16, unveiling Fortrea Intelligent Technology™ (FIT), reporting fourth-quarter and full-year 2025 results, and announcing the grant of inducement awards.

Fortrea Holdings, Inc.'s business exhibits seasonality, requiring the company to build up inventory during certain quarters. The company's CEO noted an improved demand environment, with large pharma being more constructive and biotech funding inflecting positively. Clinical trial starts have rebounded, and Fortrea observed strong double-digit growth in its pipeline of opportunities, particularly in China.

Fortrea Holdings, Inc. is a global contract research organization providing clinical development solutions to the life sciences industry, partnering with various companies to support therapy development from early to late stages. The company's services include clinical trial management, clinical pharmacology, and consulting, incorporating technology solutions like Fortrea Intelligent Technology™ (FIT) and focusing on therapeutic areas such as oncology and rare diseases.

Fortrea Holdings, Inc. has a significant global presence, operating in approximately 90 to 100 countries. The company maintains primary office locations in the United States, the United Kingdom, China, India, and Singapore, with additional field operations worldwide, enabling support for multinational clinical studies.

In the past year, Fortrea's brand reputation has been positively impacted by its focus on innovation and strategic collaborations, such as unveiling Fortrea Intelligent Technology™ (FIT) and announcing a strategic collaboration with SCTbio to advance cell therapy development. Historically, the company faced criticism for its animal testing practices when operating under the name Covance.

Fortrea Holdings Inc. stock ownership is a mix of institutional, retail, and individual investors. Institutional investors hold a significant portion of the company's stock. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Goldman Sachs Group Inc.